„Immunotherapy for the Treatment of Cancer: Mode of Action and Mode of Resistance“ Else Kröner Fresenius Clinician Scientist Program Cancer Immunotherapy Munich

Project start
Institution: University Hospital, LMU Munich
Applicant: Prof. Dr. med. Marion Subklewe
EKFS funding line: Else Kröner-Forschungskolleg
CSP Cancer Immunotherapy Munich

The Clinician Scientist Program (CSP) Cancer Immunotherapy is a scientific program with focus on tumor immunology. The CSP supports medical doctors to pursue a career in academic medicine by combining scientific and clinical work. The focus of the CSP lies within translational cancer immunotherapy. Within the last years, various novel immunotherapeutic platforms, like bispecific- or immunoregulatory antibodies, therapeutic vaccinations or gene modified T cells, were approved for clinical application. However, the mechanisms of action and associated resistance factors are incompletely understood. The goal of the CSP is to gain deeper insights into the mode of action and the mode of resistance of various immunotherapy platforms as the basis to improve relapse-free and overall survival of patients with cancer. 

Here you can get further information.